Juan Ramón Castillo Ferrando

Suggest Changes
Learn More
Hepatic impairment may impede tyrosine kinase inhibitor metabolism. This phase I study compared the pharmacokinetics of brivanib in patients with hepatocellular carcinoma (HCC) and varying levels of(More)
  • 1